Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy, including overall survival in DREAMM-7 · If approved ...

The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease. Blenrep (belantamab mafodotin) has been ...

【葛兰素史克抗癌药物Blenrep显著降低死亡风险 有望重获监管批准】葛兰素史克公司表示，其血液癌症药物在与另一种癌症治疗药物联合使用 ...

葛兰素史克称，Blenrep在与另一种名为BorDex的癌症疗法联合使用时，帮助那些骨髓瘤复发的患者们延长了寿命。这家英国制药巨头表示，后期临床试验 ...

Blenrep plus Velcade and dexamethasone significantly improves overall survival in relapsed/refractory multiple myeloma compared to Darzalex-based regimens. The DREAMM-7 trial met its secondary ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks to a key patient survival win. The antibody-drug conjugate (ADC ...

GSK hailed progress for its withdrawn blood cancer drug Blenrep on Thursday, raising the prospect of the treatment returning to market after the drugmaker announced positive trial results.

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab mafodotin) in combination with ...

GSK (GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep in combination with bortezomib plus dexamethasone as a ...